Worth reading
41Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Agreements reached under this partnership
Discontinuation130AVeritas In Silico Inc.
Alliance partnerTakeda Pharmaceutical Company Limited
About the partner
LocationOsaka City, Osaka Prefecture
Impact on Business Performance
The impact of the conclusion of this joint drug discovery research on the Company's financial results is expected to be limited, and no changes are expected to the earnings forecasts for the fiscal year ending December 2026 announced on 15 February 2026.
Contract Date19 June 2023
| Item | Details |
|---|---|
| Name of alliance partner | Takeda Pharmaceutical Company Limited |
| Alliance partner's location | Osaka City, Osaka Prefecture |
| Type of alliance | Discontinuation |
| Contract Date | 19 June 2023 |
| Impact on Business Performance | The impact of the conclusion of this joint drug discovery research on the Company's financial results is expected to be limited, and no changes are expected to the earnings forecasts for the fiscal year ending December 2026 announced on 15 February 2026. |
Items this document does not state (18)
Alliance partner's business activitiesAlliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeDetails of the allianceNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Following discussions and consideration with Takeda Pharmaceutical Company Limited, it was decided to amicably conclude the joint drug discovery research.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.